Kauer, Joseph
Freundt, Emma P.
Schmitt, Anita
Weinhold, Niels
Mai, Elias K.
Müller-Tidow, Carsten
Goldschmidt, Hartmut
Raab, Marc S.
Kriegsmann, Katharina
Sauer, Sandra
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 24 July 2023
Accepted: 10 October 2023
First Online: 21 November 2023
Declarations
:
: All patients provided written informed consent. The trial was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the Declaration of Helsinki principles, and local legal and regulatory requirements and approved by the ethics committee of the University of Heidelberg.
: Not applicable.
: Sandra Sauer: travel grants or honoraria for presentations for Celgene, BMS, Janssen, Takeda and Amgen. Anita Schmitt: travel grants from Hexal and Jazz Pharmaceuticals. Research grant from Therakos/Mallinckrodt. Consultant by Janssen-Cilag and BMS. Anita Schmitt is co-founder of TolerogenixX LtD. Anita Schmitt is part-time employee of TolerogenixX Ltd.Hartmut Goldschmidt: Grants and/or provision of Investigational Medicinal Product: Amgen, Array Biopharma/Pfizer, BMS/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi. Research Support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis. Advisory Boards: Amgen, BMS, Janssen, Sanofi, Adaptive Biotechnology. Honoraria: Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Support for attending meetings and/or travel: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Katharina Kriegsmann: Research funding from Bristol Myers Squibb and Sanofi-Aventis Deutschland GmbH.